SPDR S&P Biotech ETF Rating $160.46 0.00 (0.00%) As of 07/2/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock SPDR S&P Biotech ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XBI Aggregate RatingModerate Buy 2.73Holdings in XBI have an aggregate rating of Moderate Buy based on 380 analyst ratings issued in the past year covering 25 companies (30.5% of the portfolio).XBI Aggregate Price Target$160.46High Prediction$160.46Average Prediction$160.46Low Prediction$160.46Holdings in XBI have an aggregate price target of $160.46 and a range of $160.46 to $160.46 covering 25 companies (30.5% of the portfolio).XBI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy20 Moderate Buy rating(s)Hold2 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 XBI Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings1.48%APGEApogee Therapeutics$132.911.1626 of 5 stars2.24$121.25 -8.8%21Insider Trade1.41%MRNAModerna$79.761.1762 of 5 stars1.83$37.13 -53.4%18Gap Down1.40%TWSTTwist Bioscience$99.241.3414 of 5 stars2.80$79.30 -20.1%10Gap Up1.37%ORKAOruka Therapeutics$85.212.6606 of 5 stars2.82$134.30 57.6%11Analyst DowngradeGap UpHigh Trading Volume1.35%KYMRKymera Therapeutics$113.511.8044 of 5 stars2.96$121.41 7.0%23Trending NewsAnalyst ForecastInsider Trade1.30%VKTXViking Therapeutics$37.442.8803 of 5 stars2.79$93.60 150.0%141.29%PRAXPraxis Precision Medicines$318.523.5207 of 5 stars2.95$569.63 78.8%21Gap Up1.27%ERASErasca$18.471.5536 of 5 stars2.60$20.11 8.9%10Trending NewsGap Down1.20%CGONCG Oncology$70.363.3989 of 5 stars2.71$81.73 16.2%14News Coverage1.20%RVMDRevolution Medicines$189.241.7151 of 5 stars3.00$135.39 -28.5%22News CoverageAnalyst ForecastInsider Trade1.20%RYTMRhythm Pharmaceuticals$114.172.3391 of 5 stars2.83$133.13 16.6%18Positive NewsGap Down1.19%SLSSELLAS Life Sciences Group$14.980.4264 of 5 stars2.00$10.00 -33.2%2Gap Down1.18%DNTHDianthus Therapeutics$94.342.2693 of 5 stars2.93$117.82 24.9%14Gap Down1.18%PCVXVaxcyte$58.391.891 of 5 stars2.63$86.00 47.3%8Gap Down1.17%CYTKCytokinetics$86.492.4703 of 5 stars2.91$100.00 15.6%22Insider Trade1.16%NTRANatera$279.321.8519 of 5 stars2.86$260.33 -6.8%221.15%MIRMMirum Pharmaceuticals$125.592.3159 of 5 stars2.93$143.00 13.9%15Analyst ForecastInsider TradeGap Down1.15%ROIVRoivant Sciences$35.131.8376 of 5 stars2.75$33.59 -4.4%12Insider Trade1.15%SRRKScholar Rock$54.881.5773 of 5 stars3.12$56.00 2.0%17Gap Down1.14%RAREUltragenyx Pharmaceutical$33.473.8463 of 5 stars2.82$59.56 78.0%17Positive NewsGap Down1.14%COGTCogent Biosciences$38.691.5869 of 5 stars2.86$43.73 13.0%141.12%TVTXTravere Therapeutics$56.900.0%1.893 of 5 stars2.69$52.08 -8.5%13News CoveragePositive News1.10%CELCCelcuity$107.952.798 of 5 stars2.83$152.09 40.9%121.10%ALKSAlkermes$54.581.7527 of 5 stars2.72$49.63 -9.1%18Analyst ForecastInsider TradeGap Down1.10%KRYSKrystal Biotech$375.072.5447 of 5 stars2.83$340.56 -9.2%12Analyst Downgrade This page (NYSEARCA:XBI) was last updated on 7/4/2026 by MarketBeat.com Staff. From Our PartnersWorld’s Largest Investors Are Moving Their Money (Not Into AI)While headlines focus on the next AI IPO, the world's largest investors are moving capital into one asset at t...Stansberry Research | SponsoredGoldman Sachs: 300 million jobs will disappearGoldman Sachs predicts 300 million jobs will disappear - and Elon Musk's 'Project Apex' AI supercomputer is ac...InvestorPlace | SponsoredURGENT Dollar Reset Warning for MondayA 50-year U.S.-Saudi arrangement established under Henry Kissinger - one credited with anchoring the dollar in...Golden Portfolio | SponsoredThe semiconductor stock supplying Apple and SpaceX on fire in 2026A semiconductor company supplying both Apple and SpaceX just doubled its data center revenue forecast to 1 bil...Weiss Ratings | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
